Proteomic analysis indicates altered expression of plasma proteins in a rat nephropathy model

Clinical and Experimental Nephrology

Volumn 17, Issue 1, 2013, Pages 24-31

  Ai, Si ^a   Zheng, Jian ^a   Lin, Qing ^a   Chen, Rongyan ^a  

^a FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

CM10 protein chip; Doxorubicin induced nephropathy; Prednisone; Proteomics; SELDI TOF MS

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CHOLESTEROL; DOXORUBICIN; NITROGEN; PLASMA PROTEIN; PREDNISONE; TRIACYLGLYCEROL; UREA;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; MALE; MINIMAL CHANGE GLOMERULONEPHRITIS; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN URINE LEVEL; PROTEOMICS; RAT; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PROTEINS; DATABASES, PROTEIN; DISEASE MODELS, ANIMAL; DOXORUBICIN; GLUCOCORTICOIDS; MALE; NEPHROSIS, LIPOID; PREDNISONE; PROTEIN ARRAY ANALYSIS; PROTEINURIA; PROTEOMICS; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TIME FACTORS;

EID: 84874113159     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-012-0662-y     Document Type: Article

References (41)

1. Lane JC, Kaskel FJ. Pediatric nephrotic syndrome: from the simple to the complex. Semin Nephrol. 2009;29:389-98.
2. Cameron JS, Turner DR, Ogg CS, Sharpstoner P, Brown CB. The nephrotic syndrome in adults with 'minimal change' glomerular lesions. Q J Med. 1974;43:461-88.
3. He K, Li R. Analysis on wean refractory nephropathy. Chin J Pract Integr Med. 2004;4:2621-2.
4. Yue Z, Min W, Qian W, Fei C, Jing Y, Boguang L, et al. Study on the establishment of the model of minimal change nephropathy with adriamycin in rats. J Beijing Univ TCM. 2002;3:16-8.
5. Traum AZ, Schachter AD. Proteomic analysis in pediatric renal disease. Semin Nephrol. 2007;27:652-7.
6. Yoshida Y, Miyamoto M, Bo X, Yaoita E, Yamamoto T. Overview of kidney and urine proteome databases. Contrib Nephrol. 2008;160:186-97.
7. Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics. 2004;4:3665-85.
8. De Bock M, de Seny D, Meuwis MA, Chapelle JP, Louis E, Malaise M, et al. Challenges for biomarker discovery in body fluids usingSELDI-TOF-MS. J Biomed Biotechnol. 2010;2010:906082.
9. Merchant ML, Klein JB. Proteomics and diabetic nephropathy. Semin Nephrol. 2007;27:627-36.
10. Yoshida Y, Miyazaki K, Kamiie J, Sato M, Okuizumi S, Kenmochi A, et al. Two-dimensional electrophoretic profiling of normal human kidney glomerulus proteome and construction of an extensible markup language (XML)-based database. Proteomics. 2005;5:1083-96.
11. Miyamoto M, Yoshida Y, Taguchi I, Nagasaka Y, Tasaki M, Zhang Y, et al. In-depth proteomic profiling of the normal human kidney glomerulus using two-dimensional protein prefractionation in combination with liquid chromatography-tandem mass spectrometry. J Proteome Res. 2007;6:3680-90.
12. Oh J, Pyo JH, Jo EH, Hwang SI, Kang SC, Jung JH, et al. Establishment of a near-standard two-dimensional human urine proteomic map. Proteomics. 2004;4:3485-97.
13. Pieper R, Gatlin CL, McGrath AM, Makusky AJ, Mondal M, Seonarain M, et al. Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics. 2004;4:1159-74.
14. Khan A, Packer NH. Simple urinary sample preparation for proteomic analysis. J Proteome Res. 2006;5:2824-38.
15. Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA. 2004;101:13368-73.
16. Hawkridge AM, Muddiman DC. Mass spectrometry-based biomarker discovery: toward a global proteome index of individuality. Annu Rev Anal Chem. 2009;2:265-77.
17. Sparbier K, Wenzel T, Dihazi H. Immuno-MALDI-TOF MS, new perspectives for clinical applications of mass spectrometry. Proteomics. 2009;9:1442-50.
18. Hutchens T, Yip T. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectrom. 1993;7:576-80.
19. ® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis. 1999;2:264-76.
20. Wright GL Jr. SELDI protein chip MS: a platform for biomarker discovery and cancer diagnosis. Expert Rev Mol Diag. 2002;2:549-63.
21. Tang N, Tornatore P, Weinberger SR. Current developments in SELDI affinity technology. Mass Spectrom Rev. 2004;23:34-44.
22. Zhao H, Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R, Brooks JD. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med. 2006;3:e13.
23. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol. 2006;24:5070-8.
24. Liu LL, Qin Y, Cai JF, Wang HY, Tao JL, Li H, et al. Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome. Clin Immunol. 2011;139:314-20.
25. Matsumotoa K, Kanmatsuse K. Increased urinary excretion of interleukin-17 in nephrotic patients. Nephron. 2002;91:243-9.
26. Puppione DL, Ryan CM, Bassilian S, Souda P, Xiao X, Ryder OA, et al. Detection of two distinct forms of apoC-I in great apes. Comp Biochem Physiol Part D Genomics Proteomics. 2010;5:73-9.
27. +-ATPase regulatory gamma-subunit in rat kidney. Am J Physiol Renal Physiol. 2002;282:393-407.
28. Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R, et al. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol. 1997;151:1141-52.
29. Gonzalez E, Neuhaus T, Kemper MJ, Giradin E. Proteomic analysis of mononuclear cells of patients with minimal-change nephrotic syndrome of childhood. Nephrol Dial Transplant. 2009;24:149-55.
30. Bertani T, Poggi A, Pozzoni R, Delaini F, Sacchi G, Thoua Y, et al. Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab Invest. 1982;46:16-23.
31. Bricio T, Molina A, Egido J, Gonzalez E, Mampaso F. IL-1-like production in adriamycin-induced nephrotic syndrome in the rat. Clin Exp Immunol. 1992;87:117-21.
32. Ishikawa I, Hayama T, Yoshida S, Asaka M, Tomosugi N, Watanabe M, et al. Proteomic analysis of rat plasma by SELDI-TOF-MS under the condition of prevention of progressive adriamycin nephropathy using oral adsorbent AST-120. Nephron Physiol. 2006;103:125-30.
33. Hammer E, Bien S, Salazar MG, Steil L, Scharf C, Hildebrandt P, et al. Proteomic analysis of doxorubicin-induced changes in the proteome of HepG2cells combining 2-D DIGE and LC-MS/MS approaches. Proteomics. 2010;10:99-114.
34. Chen Y, Daosukho C, Wycliffe O, Turner DM, Pierce WM, Klein JB, et al. Redox proteomic identification of oxidized cardiac proteins in Adriamycin-treated mice. Free Radic Biol Med. 2006;41:1470-7.
35. Coulter PM 2nd, Bautista EA, Margulies JE, Watson JB. Identification of cortexin: a novel, neuron-specific, 82-residue membrane protein enriched in rodent cerebral cortex. J Neurochem. 1993;61:756-9.
36. Wang HT, Chang JW, Guo Z, Li BG. In silico-initiated cloning and molecular characterization of cortexin 3, a novel human gene specifically expressed in the kidney and brain, and well conserved in vertebrates. Int J Mol Med. 2007;20:501-10.
37. Chakraborty S, Khan GA, Karmohapatra SK, Bhattacharya R, Bhattacharya G, Sinha AK. Purification and mechanism of action of "cortexin", a novel antihypertensive protein hormone from kidney and its role in essential hypertension in men. J Am Soc Hypertens. 2009;3:119-32.
38. Kontchou LM, Liccioli G, Pela I. Blood pressure in children with minimal change nephrotic syndrome during oedema and after steroid therapy: the influence of familial essential hypertension. Kidney Blood Press Res. 2009;32:258-62.
39. Gipson DS, Massengill SF, Yao L, Nagaraj S, Smoyer WE, Mahan JD, et al. Management of childhood onset nephrotic syndrome. Pediatrics. 2009;124:747-57.
40. LaBaer J. So, you want to look for biomarkers? J Proteome Res. 2005;4:1053-9.
41. Knepper MA. Common sense approaches to urinary biomarker study design. J Am Soc Nephrol. 2009;20:1175-8.